References

• 1994Lifetime and 12-Month Prevalence of DSM-III-R Psychiatric Disorders in the United States12,377 cited
• 2011The size and burden of mental disorders and other disorders of the brain in Europe 20103,749 cited
• 2012Twelve‐month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States2,944 cited
• 2005Prevalence and Treatment of Mental Disorders, 1990 to 20031,911 cited
• 2004Prevalence, co-morbidity and correlates of mental disorders in the general population: results from the German Health Interview and Examination Survey (GHS)1,097 cited
• 2008World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision862 cited
• 2014Psychische Störungen in der Allgemeinbevölkerung749 cited
• 2014Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology710 cited
• 2005Prevalence and Treatment of Mental Disorders650 cited
• 2010PRISMA Statement630 cited
• 2005Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology630 cited
• 2002Generalized anxiety and depression in primary care: prevalence, recognition, and management.518 cited
• 2015